News & Updates

Show Multimedia Only

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Patients with type 2 diabetes mellitus (T2DM) who use glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have lower odds of peptic ulcer disease when compared with insulin users, as shown in a retrospective study.

GLP-1 RA use in T2DM may protect against peptic ulcer disease

02 Sep 2025

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025 by

Combination treatment with the oral, highly selective FGFR4 inhibitor irpagratinib plus atezolizumab has shown promising efficacy in patients with untreated or immune checkpoint inhibitor (ICI)-exposed hepatocellular carcinoma (HCC) with fibroblast growth factor 19 overexpression (FGF19+), while being safe and well tolerated, according to the updated results of the phase II ABSK-011-201 study.

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

02 Sep 2025

Desensitization feasible in patients with HSRs to chemotherapy

02 Sep 2025

Total dose desensitization is successful in patients with hypersensitivity reactions (HSRs) to chemotherapy, suggests a study.

Desensitization feasible in patients with HSRs to chemotherapy

02 Sep 2025

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

02 Sep 2025 by

The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1‒ persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

02 Sep 2025

Does aprepitant influence response to DICEP?

02 Sep 2025

A recent study in Canada has shown similar response rates to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) in patients with relapsed/refractory Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL) regardless of aprepitant use.

Does aprepitant influence response to DICEP?

02 Sep 2025

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service

02 Sep 2025 by

Patients labelled as allergic to penicillin or other beta-lactam antibiotics face a significantly higher risk of periprosthetic joint infection (PJI) up to 5 years following knee arthroplasty, and should be prioritized for preoperative allergy assessment, researchers from the University of Hong Kong (HKU) have found.

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service

02 Sep 2025

Uveitis risk reduced with GLP-1RAs

01 Sep 2025

Users of glucagon-like peptide-1 receptor agonists (GLP-1RAs) are at lower risk of uveitis compared with nonusers, according to a retrospective study.

Uveitis risk reduced with GLP-1RAs

01 Sep 2025

Pembrolizumab prolongs real-world survival in NSCLC patients

01 Sep 2025

Treatment with pembrolizumab demonstrates effectiveness in improving progression-free survival (PFS) and overall survival (OS) in real clinical practice, results of a study have shown.

Pembrolizumab prolongs real-world survival in NSCLC patients

01 Sep 2025

CYP3A5-guided tacrolimus dosing tied to faster achievement of target trough levels in kidney recipients

01 Sep 2025 by

The local ethnic population of kidney transplant recipients in Singapore has a diverse CYP3A5 genotype expression, according to a study. A CYP3A5-guided dosing of tacrolimus may help these patients achieve target trough levels at a faster rate, but it can also put them at greater risk of hyperkalaemia.

CYP3A5-guided tacrolimus dosing tied to faster achievement of target trough levels in kidney recipients

01 Sep 2025

Upadacitinib bumps up GCA treatment armamentarium

01 Sep 2025 by

The primary results of the phase III SELECT-GCA trial underpin the potential of upadacitinib plus a glucocorticoid taper (GC-T) for the treatment of giant-cell arteritis (GCA).

Upadacitinib bumps up GCA treatment armamentarium

01 Sep 2025

News & Updates

Filter by Specialty:

Specialty:

GLP-1 RA use in T2DM may protect against peptic ulcer disease

GLP-1 RA use in T2DM may protect against peptic ulcer disease

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

Irpagratinib plus atezolizumab combo active against FGF19+ HCC

Desensitization feasible in patients with HSRs to chemotherapy

Desensitization feasible in patients with HSRs to chemotherapy

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer

Does aprepitant influence response to DICEP?

Does aprepitant influence response to DICEP?

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service

Mislabelled beta-lactam antibiotic allergy linked to post-TKA joint infection, prompts allergy delabelling service

Uveitis risk reduced with GLP-1RAs

Uveitis risk reduced with GLP-1RAs

Pembrolizumab prolongs real-world survival in NSCLC patients

Pembrolizumab prolongs real-world survival in NSCLC patients

CYP3A5-guided tacrolimus dosing tied to faster achievement of target trough levels in kidney recipients

CYP3A5-guided tacrolimus dosing tied to faster achievement of target trough levels in kidney recipients

Upadacitinib bumps up GCA treatment armamentarium

Upadacitinib bumps up GCA treatment armamentarium